Multicentric breast cancer means two or more separate tumors are found in different quadrants of the same breast. Unlike a single tumor that has grown large, these are distinct cancer foci separated by normal tissue, each developing in a different area. It accounts for roughly 5 to 10% of all breast cancer diagnoses, though rates climb when MRI is used for detection.
Multicentric vs. Multifocal Cancer
These two terms sound similar but refer to different patterns. Multifocal breast cancer means multiple tumors exist within the same quadrant of the breast. Multicentric breast cancer means tumors are found in different quadrants. The breast is divided into four quadrants (upper outer, upper inner, lower outer, lower inner), and when cancer appears in more than one of those zones, it’s classified as multicentric.
The distinction matters because multicentric disease historically carried different surgical implications. Together, multifocal and multicentric cancers make up about 10 to 24% of all breast cancer cases, with multifocal being the more common of the two.
Where Do the Tumors Come From?
One of the key questions researchers have studied is whether these separate tumors are offshoots from a single original cancer or whether they developed independently. The answer is: it depends. In at least 25% of multicentric cases, the tumor foci appear to be polyclonal, meaning they arose independently rather than spreading from one source. The remaining cases may share a common origin, with cancer cells migrating through breast tissue or ducts to establish new sites.
This has practical consequences. When tumors develop independently, they can have different biological characteristics. Studies show that 5 to 10% of multifocal or multicentric cancers have discordant hormone receptor status between the different tumor sites. One tumor might be estrogen receptor positive while another is not. This is why pathologists typically test each tumor focus separately.
How It’s Found
Many multicentric cancers are discovered when imaging reveals additional suspicious areas beyond the tumor that initially brought a patient in. MRI is significantly better at catching these extra foci than mammography alone. In a study published in the American Journal of Roentgenology, MRI detected 81% of cancer foci compared to 66% for mammography. The gap was even wider in women with dense breast tissue, where mammography’s sensitivity dropped to 60% while MRI held steady at 81%.
This is one reason your care team may recommend a breast MRI after an initial cancer diagnosis. Finding all tumor sites before surgery changes the treatment plan considerably, and missing a second or third focus can lead to incomplete treatment.
Lymph Node Risk
Multicentric breast cancer carries a notably higher risk of lymph node involvement than single-tumor disease. Research comparing the two found that lymph node metastasis rates were about 25% in multicentric cases versus roughly 10% in unifocal tumors. That difference is statistically significant and influences both staging and treatment decisions.
The higher lymph node risk likely reflects the greater overall tumor burden. Even though each individual tumor may be small, having cancer established in multiple areas of the breast increases the chance that cells have reached the lymphatic system.
How Staging Works With Multiple Tumors
You might expect that doctors add the sizes of all the tumors together to determine the cancer’s stage, but that’s not how it works. Under the current TNM staging system (8th edition), only the largest tumor focus determines the T-stage. So if you have a 2 cm tumor in one quadrant and a 1 cm tumor in another, your cancer is staged based on the 2 cm tumor alone.
This approach has been debated because it may underestimate the total disease burden. Some research has explored whether using the combined size of all tumors would better predict outcomes, but the single-largest-focus rule remains the standard.
Surgical Options
Mastectomy was long considered the standard treatment for multicentric disease because the tumors span different areas of the breast, making it harder to remove everything with a single smaller surgery. That thinking has evolved. A 2024 systematic review and meta-analysis found that breast-conserving therapy (lumpectomy plus radiation) produced comparable local recurrence rates to mastectomy in multicentric patients.
That said, the same analysis showed that multicentric patients who had breast-conserving surgery did have a somewhat higher local recurrence rate compared to patients with a single tumor (about 1.76 times higher). But this gap has been shrinking in more recent studies, likely due to better imaging, more precise surgical techniques, and improved radiation planning.
Whether breast conservation is feasible depends on several factors: the size and location of each tumor, the overall breast size relative to the amount of tissue that needs to be removed, and whether clear margins can be achieved at every site. Some patients with multicentric disease are good candidates for lumpectomy, while others are better served by mastectomy.
Radiation Considerations
When breast-conserving surgery is chosen, whole-breast radiation is the standard follow-up. Accelerated partial-breast irradiation, which targets only the area around the tumor bed, is generally not recommended for multicentric disease. Guidelines from the American Society of Breast Surgeons specifically exclude multicentric cancers from partial-breast irradiation protocols. Multifocal disease (tumors in the same quadrant) may qualify for partial-breast radiation if the combined tumor area is 3 cm or smaller, but multicentric cases require the broader coverage of whole-breast treatment.
Long-Term Outlook
Despite the added complexity of multiple tumor sites, long-term survival for multicentric breast cancer is reassuringly similar to unifocal disease when matched for stage and treatment. A study examining 10-year outcomes found overall survival rates of 74% for multifocal and multicentric patients compared to 75% for those with a single tumor. Disease-free survival was 61% versus 66%, and neither difference was statistically significant.
These numbers reinforce that the number of tumor foci alone doesn’t determine prognosis. What matters more is the biology of the tumors (hormone receptor status, grade, growth rate), whether lymph nodes are involved, and how well the cancer responds to treatment. The presence of multiple sites does increase the complexity of treatment planning, but it doesn’t automatically mean a worse outcome.